Ting

Tolnaftate


Insight Pharmaceuticals Llc
Human Otc Drug
NDC 63736-051
Ting also known as Tolnaftate is a human otc drug labeled by 'Insight Pharmaceuticals Llc'. National Drug Code (NDC) number for Ting is 63736-051. This drug is available in dosage form of Cream. The names of the active, medicinal ingredients in Ting drug includes Tolnaftate - 10 mg/g . The currest status of Ting drug is Active.

Drug Information:

Drug NDC: 63736-051
The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC.
Proprietary Name: Ting
Also known as the trade name. It is the name of the product chosen by the labeler.
Product Type: Human Otc Drug
Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the “Document Type” of the SPL submission for the listing.
Non Proprietary Name: Tolnaftate
Also known as the generic name, this is usually the active ingredient(s) of the product.
Labeler Name: Insight Pharmaceuticals Llc
Name of Company corresponding to the labeler code segment of the ProductNDC.
Dosage Form: Cream
The translation of the DosageForm Code submitted by the firm. There is no standard, but values may include terms like `tablet` or `solution for injection`.The complete list of codes and translations can be found www.fda.gov/edrls under Structured Product Labeling Resources.
Status: Active
FDA does not review and approve unfinished products. Therefore, all products in this file are considered unapproved.
Substance Name:TOLNAFTATE - 10 mg/g
This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted.
Route Details:TOPICAL
The translation of the Route Code submitted by the firm, indicating route of administration. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.

Marketing Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Marketing Category: OTC MONOGRAPH FINAL
Product types are broken down into several potential Marketing Categories, such as New Drug Application (NDA), Abbreviated New Drug Application (ANDA), BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.
Marketing Start Date: 08 Jun, 2009
This is the date that the labeler indicates was the start of its marketing of the drug product.
Marketing End Date: 15 Jan, 2025
This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached.
Application Number: part333C
This corresponds to the NDA, ANDA, or BLA number reported by the labeler for products which have the corresponding Marketing Category designated. If the designated Marketing Category is OTC Monograph Final or OTC Monograph Not Final, then the Application number will be the CFR citation corresponding to the appropriate Monograph (e.g. “part 341”). For unapproved drugs, this field will be null.
Listing Expiration Date: 31 Dec, 2023
This is the date when the listing record will expire if not updated or certified by the firm.

OpenFDA Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Manufacturer Name:Insight Pharmaceuticals LLC
Name of manufacturer or company that makes this drug product, corresponding to the labeler code segment of the NDC.
RxCUI:103951
209652
The RxNorm Concept Unique Identifier. RxCUI is a unique number that describes a semantic concept about the drug product, including its ingredients, strength, and dose forms.
Original Packager:Yes
Whether or not the drug has been repackaged for distribution.
UNII:06KB629TKV
Unique Ingredient Identifier, which is a non-proprietary, free, unique, unambiguous, non-semantic, alphanumeric identifier based on a substance’s molecular structure and/or descriptive information.

Packaging Information:

Package NDCDescriptionMarketing Start DateMarketing End DateSample Available
63736-051-011 TUBE in 1 BOX (63736-051-01) / 14 g in 1 TUBE08 Jun, 2009N/ANo
Package NDC number, known as the NDC, identifies the labeler, product, and trade package size. The first segment, the labeler code, is assigned by the FDA. Description tells the size and type of packaging in sentence form. Multilevel packages will have the descriptions concatenated together.

Purpose:

Purpose antifungal

Product Elements:

Ting tolnaftate tolnaftate tolnaftate butylated hydroxytoluene polyethylene glycol 400 polyethylene glycol 3350 titanium dioxide petrolatum

Indications and Usage:

Uses for effective treatment of most athlete's foot (tinea pedis), jock itch (tinea cruris) and ringworm (tinea corporis) for effective relief of itchy, scaly skin between toes clears up most athlete's foot infection and with daily use helps keep it from coming back

Warnings:

Warnings for external use only do not use on children under 2 years of age unless directed by a doctor when using this product avoid contact with the eyes stop use and ask a doctor if irritation occurs or if there is no improvement within 4 weeks (for athlete's foot and ringworm) irritation occurs or if there is no improvement within 2 weeks (for jock itch) keep out of reach of children if swallowed, get medical help or contact a poison control center right away.

Do Not Use:

Warnings for external use only do not use on children under 2 years of age unless directed by a doctor when using this product avoid contact with the eyes stop use and ask a doctor if irritation occurs or if there is no improvement within 4 weeks (for athlete's foot and ringworm) irritation occurs or if there is no improvement within 2 weeks (for jock itch) keep out of reach of children if swallowed, get medical help or contact a poison control center right away.

When Using:

When using this product avoid contact with the eyes

Dosage and Administration:

Directions clean the affected area and dry thoroughly apply a thin layer of the product over affected area twice daily (morning and night) or as directed by a doctor supervise children in the use of this product for athlete's foot use daily for 4 weeks. if condition persists longer, consult a doctor. pay special attention to the spaces between the toes. wear well-fitting, ventilated shoes and change shoes and socks at least once daily. to prevent athlete's foot, clean feet and dry thoroughly, then apply a thin layer of product to feet once or twice daily (morning and/or night) following the above directions. for ringworm use daily for 4 weeks. if condition persists longer, consult a doctor. for jock itch use daily for 2 weeks. if condition persists longer, consult a doctor. this product is not effective on the scalp or nails.

Stop Use:

Stop use and ask a doctor if irritation occurs or if there is no improvement within 4 weeks (for athlete's foot and ringworm) irritation occurs or if there is no improvement within 2 weeks (for jock itch)

Package Label Principal Display Panel:

Principal display panel ting tolnaftate antifungal cream net wt. 0.5 oz (14 g) ting antifungal cream carton


Comments/ Reviews:

* Data of this site is collected from www.fda.gov. This page is for informational purposes only. Always consult your physician with any questions you may have regarding a medical condition.